Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. Keeping that in mind, here is one stock where Wall Street’s positive outlook is supported by strong fundamentals and two where analysts may be overlooking some important risks.
Two Stocks to Sell:
Gibraltar (ROCK)
Consensus Price Target: $75.25 (68.9% implied return)
Gibraltar (NASDAQ: ROCK) makes renewable energy, agriculture technology and infrastructure products. Its mission statement is to make everyday living more sustainable.
Why Do We Think Twice About ROCK?
- Sales trends were unexciting over the last five years as its 3.8% annual growth was below the typical industrials company
- Falling earnings per share over the last two years has some investors worried as stock prices ultimately follow EPS over the long term
- 6× net-debt-to-EBITDA ratio makes lenders less willing to extend additional capital, potentially necessitating dilutive equity offerings
Gibraltar is trading at $44.55 per share, or 10.5x forward P/E. Dive into our free research report to see why there are better opportunities than ROCK.
Evolent Health (EVH)
Consensus Price Target: $5.77 (38.2% implied return)
Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE: EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions.
Why Are We Wary of EVH?
- Disappointing average lives on platform over the past two years imply it may need to invest in improvements to get back on track
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
- High net-debt-to-EBITDA ratio of 7× could force the company to raise capital on unfavorable terms if market conditions deteriorate
Evolent Health’s stock price of $4.18 implies a valuation ratio of 11.9x forward P/E. To fully understand why you should be careful with EVH, check out our full research report (it’s free).
One Stock to Buy:
LPL Financial (LPLA)
Consensus Price Target: $430 (23.8% implied return)
As the nation's largest independent broker-dealer with no proprietary products of its own, LPL Financial (NASDAQ: LPLA) provides technology, compliance, and business support services to independent financial advisors and institutions who manage investments for retail clients.
Why Is LPLA a Good Business?
- Impressive 33.9% annual revenue growth over the last two years indicates it’s winning market share this cycle
- Share buybacks catapulted its annual earnings per share growth to 27.1%, which outperformed its revenue gains over the last five years
- Industry-leading 37.1% return on equity demonstrates management’s skill in finding high-return investments
At $347.36 per share, LPL Financial trades at 12.9x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
